Study of a new treatment for active lupus nephritis
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called O-triple for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if it can control the disease and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old
- You must have a confirmed diagnosis of lupus and a kidney biopsy showing active lupus nephritis
- You must have significant protein in your urine, indicating kidney involvement
- You must have received at least one dose of intravenous steroid treatment for the current kidney flare within the last month
- You must not be pregnant or breastfeeding
- Your kidney function must not be severely impaired
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called obinutuzumab for people with lupus kidney disease (specifically class V membranous nephropathy) who have protein in their urine. The goal is to see if this treatment can reduce protein leakage and preserve kidney function.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests a new medicine called SIM0278 for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the drug can help control the disease and improve kidney health.
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.